Michael Cherny
Stock Analyst at Leerink Partners
(2.51)
# 1,354
Out of 4,667 analysts
123
Total ratings
50%
Success rate
-1.69%
Average return
Main Sectors:
Stocks Rated by Michael Cherny
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IQV IQVIA Holdings | Reiterates: Outperform | $260 → $248 | $194.57 | +27.46% | 2 | Nov 19, 2024 | |
| ICLR ICON Public Limited Company | Reiterates: Outperform | $270 → $255 | $207.94 | +22.63% | 3 | Nov 19, 2024 | |
| PGNY Progyny | Maintains: Buy | $22 → $21 | $14.47 | +45.16% | 9 | Nov 13, 2024 | |
| XRAY DENTSPLY SIRONA | Downgrades: Market Perform | n/a | $18.71 | - | 8 | Nov 7, 2024 | |
| NVST Envista Holdings | Upgrades: Market Perform | $16 → $23 | $21.05 | +9.26% | 10 | Oct 31, 2024 | |
| HIMS Hims & Hers Health | Maintains: Buy | $23 → $25 | $23.04 | +8.51% | 9 | Oct 21, 2024 | |
| MCK McKesson | Maintains: Outperform | $665 → $630 | $626.22 | +0.60% | 10 | Oct 7, 2024 | |
| COR Cencora | Maintains: Outperform | $277 → $275 | $243.58 | +12.90% | 3 | Oct 7, 2024 | |
| PDCO Patterson Companies | Maintains: Neutral | $27 → $24 | $20.06 | +19.64% | 21 | Sep 5, 2024 | |
| CVS CVS Health | Maintains: Buy | $95 → $77 | $56.85 | +35.44% | 10 | May 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $2.65 | +845.18% | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $23 → $22 | $8.23 | +167.48% | 2 | Mar 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $135 | $162.74 | -17.05% | 1 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $125 | $122.08 | +2.39% | 9 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $260 | $238.55 | +8.99% | 1 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $23 | $22.47 | +0.13% | 5 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $8 | $4.26 | +88.01% | 5 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $32 | $48.95 | -34.63% | 1 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $19 | $9.51 | +99.89% | 1 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $310 | $225.27 | +37.61% | 1 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $78 | $72.38 | +7.77% | 1 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $16 | $3.53 | +353.26% | 7 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $17 | $9.64 | +76.35% | 1 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $113 → $53 | $11.20 | +368.63% | 2 | Jan 5, 2022 |
IQVIA Holdings
Nov 19, 2024
Reiterates: Outperform
Price Target: $260 → $248
Current: $194.57
Upside: +27.46%
ICON Public Limited Company
Nov 19, 2024
Reiterates: Outperform
Price Target: $270 → $255
Current: $207.94
Upside: +22.63%
Progyny
Nov 13, 2024
Maintains: Buy
Price Target: $22 → $21
Current: $14.47
Upside: +45.16%
DENTSPLY SIRONA
Nov 7, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $18.71
Upside: -
Envista Holdings
Oct 31, 2024
Upgrades: Market Perform
Price Target: $16 → $23
Current: $21.05
Upside: +9.26%
Hims & Hers Health
Oct 21, 2024
Maintains: Buy
Price Target: $23 → $25
Current: $23.04
Upside: +8.51%
McKesson
Oct 7, 2024
Maintains: Outperform
Price Target: $665 → $630
Current: $626.22
Upside: +0.60%
Cencora
Oct 7, 2024
Maintains: Outperform
Price Target: $277 → $275
Current: $243.58
Upside: +12.90%
Patterson Companies
Sep 5, 2024
Maintains: Neutral
Price Target: $27 → $24
Current: $20.06
Upside: +19.64%
CVS Health
May 2, 2024
Maintains: Buy
Price Target: $95 → $77
Current: $56.85
Upside: +35.44%
Apr 22, 2024
Initiates: Outperform
Price Target: $25
Current: $2.65
Upside: +845.18%
Mar 18, 2024
Maintains: Market Perform
Price Target: $23 → $22
Current: $8.23
Upside: +167.48%
Feb 26, 2024
Initiates: Market Perform
Price Target: $135
Current: $162.74
Upside: -17.05%
Feb 26, 2024
Initiates: Outperform
Price Target: $125
Current: $122.08
Upside: +2.39%
Feb 26, 2024
Initiates: Outperform
Price Target: $260
Current: $238.55
Upside: +8.99%
Feb 26, 2024
Initiates: Market Perform
Price Target: $23
Current: $22.47
Upside: +0.13%
Feb 26, 2024
Initiates: Outperform
Price Target: $8
Current: $4.26
Upside: +88.01%
Feb 26, 2024
Initiates: Market Perform
Price Target: $32
Current: $48.95
Upside: -34.63%
Feb 26, 2024
Initiates: Market Perform
Price Target: $19
Current: $9.51
Upside: +99.89%
Feb 26, 2024
Initiates: Market Perform
Price Target: $310
Current: $225.27
Upside: +37.61%
Feb 26, 2024
Initiates: Market Perform
Price Target: $78
Current: $72.38
Upside: +7.77%
Feb 26, 2024
Initiates: Outperform
Price Target: $16
Current: $3.53
Upside: +353.26%
Feb 26, 2024
Initiates: Market Perform
Price Target: $17
Current: $9.64
Upside: +76.35%
Jan 5, 2022
Downgrades: Underperform
Price Target: $113 → $53
Current: $11.20
Upside: +368.63%